Global Dengue Vaccine Market is segmented By Product Type (CYD-TDV), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Dengue Vaccine Market Size
The Global Dengue Vaccine Market size was valued at USD million in 2023 and is estimated to reach USD million by 2031, growing at a CAGR of 10.4% during the forecast period (2024-2031). Dengue is a mosquito-borne infectious ailment that influences people and animals and is a result of the dengue virus belonging to the Flaviviridae’s circle of relatives and genus Flavivirus.
Dengue is likewise recognized as breakbone fever or “dandy fever. It is a usually transmitted ailment from human to human via the chew of an inflamed Aedes aegypti mosquito. Common signs of dengue encompass headache, excessive fever, fatigue, muscle pain, diarrhea, anemia, vomiting and pores and skin rashes. Dengue vaccine is a vaccine used to prevent dengue fever in humans. Several vaccines are under clinical trial that show promising effects, including TVD, TV003, TV005, TVDV and TV.
Source: DataM Intelligence Analysis (2021
Dengue Vaccine Market Scope
|
Metrics |
Details |
|
Market CAGR |
10.4% |
|
Segments Covered |
By Product Type, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Dengue Vaccine Market Dynamics
The increasing prevalence of dengue cases, increasing clinical trials by the key market players and rising vaccine development funds are driving the market in the forecast period.
Increasing Collaborations by the Research Institutes for the Clinical Trials of the Dengue Vaccine is Expected to Drive Market Growth.
With the upward push in dengue instances throughout the country, the Indian Council of Medical Research (ICMR) has launched an initiative to facilitate the improvement of a dengue vaccine. Vaccine producers and pharma corporations who've advanced or have the license of tetravalent dengue vaccine candidate and feature finished its segment I and segment II medical trials can collaborate with ICMR for carrying out segment III trials and the next improvement of the vaccine.
In addition, the apex biomedical studies institute will provide institutional infrastructure for project studies and development (R&D) sports and phase-III scientific trials for assessment of efficacy alongside protection and immunogenicity of tetravalent dengue vaccine candidate evolved via way of means of Indian producers or having the license for the same.
For instance, on March 4, 2022, it invited expressions of interest from Indian manufacturers who have developed potential tetravalent vaccine candidates or have a non-exclusive license of the tetravalent vaccine candidates and intend to conduct field studies as phase-III clinical trials. Therefore, the collaboration of manufacturers with the ICMR for phase-III clinical trials of the dengue vaccine is expected to drive the market in the forecast period.
Challenges During Dengue Vaccine Development are Expected to Hamper the Market Growth.
Several challenging situations have hindered the improvement of the dengue vaccine. One of those demanding situations is the structural similarities among DENV and different individuals of the Flaviviridae own circle of relative viruses, together with the Zika virus (ZIKV), Yellow fever virus (YFV), Japanese encephalitis virus (JEV) and West Nile virus (WNV).
The envelope protein (E) is each structurally conserved amongst flaviviruses and the maximum uncovered protein the immune gadget generates antibodies towards to neutralize the virus. Furthermore, lack of awareness among people about the dengue vaccine and rigid competition among existing players to develop a new vaccine are the factors to hamper the market in the forecast period.
COVID-19 Impact on Dengue Vaccine Market
The coronavirus pandemic has moderately impacted the dengue vaccine market. Pre-exposure to DENV may provide some degree of cross-protection to SARS-CoV-2 infection, rendering it less severe in the regions where DENV infections occur rampantly and regularly. Countries, where BCG vaccination is recommended (in early childhood) have also been observed to be less affected by COVID-19.
This appears true for highly DENV endemic (& BCG vaccine compliant) countries like India and Argentina but is in question for low/sporadic DENV-reporting (yet BCG vaccination compliant) countries like Iran and China, where COVID-19 had a serious impact so far. The high levels of infections and mortality in Brazil (another BCG vaccination-compliant country) have also put the theory that BCG vaccination could be protective against COVID-19. Therefore, the demand for the dengue vaccine increased.
In contrast, the pandemic has diverted resources and finances. And it has kept dengue vaccine development out of the international spotlight. The resurgence of dengue fever is a real threat during the COVID-19 pandemic. The high burden of dengue-related hospitalizations will further overwhelm an already overwhelmed healthcare system.
Therefore, the COVID-19 pandemic has further impetus the development, approval and introduction of dengue vaccines for wider use. Thus, from the above factors, the market got affected and it is expected to improve in the forecast period.
Dengue Vaccine Market Segment Analysis
CYD-TDV Vaccine Segment is Expected to Hold the Largest Market Share in the Dengue Vaccine Market
The CYD-TDV vaccine segment accounted for the largest market share in 2021. CYD-TDV is a tetravalent, live attenuated, chimeric dengue vaccine in a yellow fever 17D backbone developed by Sanofi Pasteur. The schedule evaluated in Phase III clinical trials includes three doses of vaccine (at 0, 6 and 12 months). The CYD-TDV vaccine shows benefits for efficacy for virologically confirmed dengue (VCD), efficacy for severe VCD and efficacy for hospitalization for VCD.
Additionally, a dengue preventive vaccine (CYD-TDV, Dengvaxia) has been licensed in 20 countries and is available for people aged 9 to 45. The World Health Organization recommends that only people with a confirmed dengue infection be vaccinated. Furthermore, in May 2019, Dengvaxia was acquired by the United States.
The U.S. Food and Drug Administration (FDA) uses it for children ages 9 to 16 who live in dengue-endemic areas with laboratory-confirmed dengue virus infection. Therefore, the demand for the CYD-TDV vaccine is increasing. Thus, from the above factors, the market segment accounts for the largest market share during the forecast period.
Source: DataM Intelligence Analysis (2021)
Global Dengue Vaccine Market Geographical Share
South America Region Holds the Largest Market Share in the Global Dengue Vaccine Market.
South America region accounted for the largest market share in 2021. The increasing prevalence of dengue cases, the high adoption of dengue vaccines in the region, rising mass vaccination and increasing clinical trials by the market players are the factors driving market growth in the forecast period.
For instance, the Brazilian Ministry of Health has reported the continuing spread of dengue fever in all five regions. Between 1 January and 31 May 2022, 1,104,742 cases of dengue, including 504 deaths, were reported, which represents an increase of 198% in cases compared to the same period in 2021. Therefore, there is an increase in the demand for the dengue vaccine in the region.
Furthermore, the Brazilian state of Paraná conducted a mass vaccination campaign against dengue with the tetravalent attenuated vaccine CYD-TDV. The campaign targeted thirty endemic municipalities. Thus, from the above factors, the South American region accounted for the largest market share in the forecast period.
Source: DataM Intelligence Analysis (2021)
Dengue Vaccine Market Companies
Major key players in the dengue vaccine market are Sanofi, Panacea Biotec, Biological, E. Limited, GlaxoSmithKline plc, Merck & Co., Takeda Pharmaceutical Company Ltd, Vabiotec, Panacea Biotec and Medigen Biologics.
On December 9, 2022, the European Commission (EC) granted marketing authorization for Takeda’s Qdenga [Dengue Tetravalent Vaccine (Live, Attenuated)] (TAK-003) to prevent dengue in people aged four years and above.
Takeda Pharmaceuticals:
Overview:
Takeda Pharmaceuticals is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing people better health and a brighter future worldwide. The company discovers and develops innovative biological medicines, making them accessible to patients worldwide. Takeda Pharmaceuticals R&D efforts are focused on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). The company also makes targeted R&D investments in Plasma-Derived Therapies and Vaccines.
Product Portfolio:
QDENGA [Dengue Tetravalent Vaccine (Live, Attenuated)]: QDENGA (TAK-003) is a dengue vaccine that is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four dengue virus serotypes and is designed to protect against any of these serotypes.
The Global Dengue Vaccine Market Report Would Provide an Access to an Approx. 45+ Market Data Tables, 40+ Figures and 180 Pages.
